Navigation Links
Hypertension & cholesterol medications present in water released into the St. Lawrence River
Date:1/26/2009

This press release is available in French.

Montreal, January 26, 2009 A study conducted by Universit de Montral researchers on downstream and upstream water from the Montreal wastewater treatment plant has revealed the presence of chemotherapy products and certain hypertension and cholesterol medications.

Bezafibrate (cholesterol reducing medication), enalapril (hypertension medication), methotrexate and cyclophosphamide (two products used in the treatment of certain cancers) have all been detected in wastewater entering the Montreal treatment station. However, only bezafibrate and enalapril have been detected in the treated water leaving the wastewater treatment plant and in the surface water of the St. Lawrence River, where the treated wastewater is released.

This study was conducted due to the sharp rise in drug consumption over the past few years. In 1999, according to a study by IMS Health Global Services, world drug consumption amounted to $342 billion. In 2006 that figure doubled to $643 billion. A significant proportion of the drugs consumed are excreted by the human body in urine and end up in municipal wastewater. Chemotherapy products, such as methotrexate, are excreted by the body practically unchanged (80 to 90 percent in their initial form).

Chemotherapy for fish?

The pharmaceutical compounds studied were chosen because of the large quantities prescribed by physicians. "Methotrexate and cyclophosphamide are two products very often used to treat cancer and are more likely to be found in water," says Sbastien Sauv, a professor of environmental chemistry at the Universit de Montral. "Even though they treat cancer, these two products are highly toxic. This is why we wanted to know the extent to which the fauna and flora of the St. Lawrence are exposed to them."

Method and quantities

Professor Sauv's team validated a rapid detection method (On-line SPE-LC-MS/MS ) (1) for pharmaceutical compounds under study in the raw and treated wastewater of the Montreal wastewater treatment plant.

The quantities of bezafibrate and enalapril detected in the raw wastewater, treated wastewater and surface water at the treatment station outlet are respectively 50 nanograms per litre, 35 ng L and 8 ng L for bezafibrate and 280 ng L, 240 ng L and 39ng L for enalapril.

"All in all, these quantities are minimal, yet we don't yet know their effects on the fauna and flora of the St. Lawrence," Professor Sauv explains. "It is possible that some species are sensitive to them. Other ecotoxicological studies will be necessary. As for the chemotherapy products detected in the raw wastewater but not in the treated wastewater, one question remains: did we not detect them because the treatment process succeeded in eliminating them or because our detection method is not yet sophisticated enough to detect them?"

A new threat to the aquatic environment

The release locations of wastewaters treated by the treatment stations are the main source of drug dispersion into the environment. Because of their high polarity and their acid-base character, some of the pharmaceutical compounds studied have the potential to be transported and dispersed widely in the aquatic environment. In Montreal, the wastewater treatment station treats a water volume representing 50 percent of the water treated in Quebec and has a capacity of about 7.6 million cubic metres per day, making it the largest physicochemical treatment station in the Americas. This is why it is important to develop a simple, rapid, precise and inexpensive method, Professor Sauv points out.


'/>"/>

Contact: Julie Gazaille
j.cordeau-gazaille@umontreal.ca
514-343-6796
University of Montreal
Source:Eurekalert

Related medicine news :

1. Study Finds Molecular Link Between Obesity, Hypertension
2. Hypertension Might Hinder Thinking
3. Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program
4. Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforges and Tekturnas Growth in The Hypertension Drug Market
5. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
6. Hypertension May Hit Black Males Earlier
7. Lipoprotein Levels May Predict Womens Hypertension Risk
8. Poor Sleep, Hypertension a Dangerous Combination
9. Diabetes, Hypertension Hasten Death in Alzheimers Patients
10. Viagra Bulk Effectively Cures Children with PAH (Pulmonary Arterial Hypertension)
11. Women at Higher Risk for Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are confused ... endometriosis. These women need a treatment plan to not only alleviate symptoms and ... help for preservation of fertility and ultimately achieving a pregnancy. The specialists at ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: